On Oct 24, major Wall Street analysts update their ratings for $Boston Scientific (BSX.US)$, with price targets ranging from $97 to $100.
Morgan Stanley analyst Patrick Wood maintains with a buy rating, and adjusts the target price from $92 to $100.
BofA Securities analyst Travis Steed maintains with a buy rating, and maintains the target price at $100.
Citi analyst Joanne Wuensch maintains with a buy rating.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $87 to $98.
Jefferies analyst Matthew Taylor maintains with a buy rating, and adjusts the target price from $90 to $100.
Furthermore, according to the comprehensive report, the opinions of $Boston Scientific (BSX.US)$'s main analysts recently are as follows:
Boston Scientific has delivered a quarter that exceeded expectations on all fronts, despite already high anticipations. The pause in the AVANT GUARD clinical trial studying Farapulse in persistent drug-naive patients has placed some pressure on the company's shares. It is important to note that the current pause pertains to a patient segment not currently under treatment, and there are aspects that require evaluation. The expectation is for enrollment to recommence shortly.
Boston Scientific is perceived as having 'best in medtech growth,' with increased confidence in the company's growth projection and the sustainability of its double-digit revenue expansion. It is noted that Boston Scientific possesses one of the most comprehensive pipelines in the medtech sector and that much of its revenue growth contributes positively to profit margins.
The recent pullback in Boston Scientific shares is seen as offering a 'compelling' entry point. This assessment comes despite the AVANT Guard trial setback, which is noteworthy for not being associated with a mortality event or instigated by the FDA. Furthermore, the sustained global momentum of Farapulse is anticipated to continue over the medium term.
Boston Scientific's third-quarter revenue and EPS surpassed expectations, with U.S. Farapulse sales notably doubling over the previous quarter, a performance that outpaced predictions. The company also increased its revenue and EPS guidance for 2024 and offered preliminary insights into its 2025 projections.
Expectations were notably high for Boston Scientific leading into the Q3 results, which ultimately met the anticipation. Despite the positive outcome, there was unexpected commentary about a temporary halt in the AVANT GUARD trial, which is investigating pulsed field ablation as a primary treatment for persistent atrial fibrillation. While the pause is due to some unanticipated observations that are not life-threatening, it has caused the shares to trade down even after a commendable report. It is believed that the market reaction is somewhat myopic, given that the enrollment is anticipated to continue shortly. Nonetheless, there is an understanding of the concerns regarding any issues with a crucial product that has the potential to expand the total addressable market.
Here are the latest investment ratings and price targets for $Boston Scientific (BSX.US)$ from 12 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月24日，多家華爾街大行更新了$波士頓科學 (BSX.US)$的評級，目標價介於97美元至100美元。
摩根士丹利分析師Patrick Wood維持買入評級，並將目標價從92美元上調至100美元。
美銀證券分析師Travis Steed維持買入評級，維持目標價100美元。
花旗分析師Joanne Wuensch維持買入評級。
富國集團分析師Larry Biegelsen維持買入評級，並將目標價從87美元上調至98美元。
富瑞集團分析師Matthew Taylor維持買入評級，並將目標價從90美元上調至100美元。
此外，綜合報道，$波士頓科學 (BSX.US)$近期主要分析師觀點如下：
波士頓科學在各方面均超出預期實現了該季度的業績，儘管預期已經很高。研究Farapulse用於持續用藥原始患者的AVANt GUARD臨床試驗的暫停對公司股價造成了一定壓力。有必要注意，目前的暫停涉及的患者群體目前並未接受治療，並且有一些需要評估的方面。預計很快將恢復招募。
波士頓科學被認爲具有『醫療科技增長最佳』，對該公司的增長預期和其兩位數營收擴張的可持續性增加了信心。值得注意的是，波士頓科學在醫療科技領域擁有最爲全面的產品線之一，並且其中很大一部分的營收增長對利潤率產生了積極影響。
波士頓科學股票最近的回落被視爲一個『引人注目』的入場點。儘管AVANt Guard試驗出現了挫折，但值得注意的是它並非與死亡事件有關或由FDA發起。此外，預計Farapulse在全球的持續勢頭將在中期內持續。
波士頓科學第三季度的營業收入和每股收益超出預期，美國Farapulse銷售額較上一季度翻了一番，超出了預期表現。該公司還增加了2024年的營收和每股收益指導，並對2025年的預測提供了初步見解。
對於波士頓科學在Q3成果之前的預期明顯很高，最終符合了期望。儘管結果是積極的，但有關AVANt GUARD試驗暫時停止的意外評論卻引人意外，該試驗是將脈衝場消融作爲持續性心房顫動的主要治療而進行的。雖然暫停是由一些意外觀察引起的，這些觀察並非危及生命，但導致股價下跌，即使在一份令人欽佩的報告之後也是如此。市場反應被認爲有些目光短淺，因爲預計招生將很快繼續。儘管如此，對於任何可能擴大總可尋址市場的關鍵產品存在問題的擔憂是可以理解的。
以下爲今日12位分析師對$波士頓科學 (BSX.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
